Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:60081 |
Name | triple-receptor negative breast cancer |
Definition | A breast cancer that is characterized by the absence of estrogen, progresterone and Her2 receptors. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer triple-receptor negative breast cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PTEN loss | AZD8186 | triple-receptor negative breast cancer | predicted - sensitive | detail... |
ERBB3 positive | Lumretuzumab | triple-receptor negative breast cancer | sensitive | detail... |
PTEN loss | AZD6482 + Talazoparib | triple-receptor negative breast cancer | sensitive | detail... |
PTEN loss | AZD6482 + Niraparib | triple-receptor negative breast cancer | sensitive | detail... |
PTEN loss | AZD6482 + Olaparib | triple-receptor negative breast cancer | sensitive | detail... |
PTEN loss | AZD6482 + Rucaparib | triple-receptor negative breast cancer | sensitive | detail... |
PTEN loss | AZD6482 + Veliparib | triple-receptor negative breast cancer | sensitive | detail... |
PIK3CA mutant | Palbociclib + Pictilisib | triple-receptor negative breast cancer | sensitive | detail... |
PIK3CA wild-type | Palbociclib + Pictilisib | triple-receptor negative breast cancer | no benefit | detail... |
PTEN loss RB1 loss | Palbociclib + Pictilisib | triple-receptor negative breast cancer | no benefit | detail... |
PTEN loss RB1 loss | Pictilisib | triple-receptor negative breast cancer | resistant | detail... |
PTEN loss RB1 loss | Palbociclib | triple-receptor negative breast cancer | resistant | detail... |
SRC positive | KX2-391 | triple-receptor negative breast cancer | sensitive | detail... |
SRC positive | KX2-391 + Paclitaxel | triple-receptor negative breast cancer | sensitive | detail... |
JAK2 over exp | NVP-BSK805 + Paclitaxel | triple-receptor negative breast cancer | sensitive | detail... |
JAK2 amp | NVP-BSK805 + Paclitaxel | triple-receptor negative breast cancer | sensitive | detail... |
JAK2 amp | NVP-BSK805 | triple-receptor negative breast cancer | sensitive | detail... |
TP53 R280K | YW3-56 | triple-receptor negative breast cancer | sensitive | detail... |
PIK3CA mutant | Pictilisib | triple-receptor negative breast cancer | sensitive | detail... |
PIK3CA amp | Linsitinib + Pictilisib | triple-receptor negative breast cancer | sensitive | detail... |
PIK3CA amp | NVP-AEW541 + Pictilisib | triple-receptor negative breast cancer | sensitive | detail... |
TP53 mutant | Carboplatin + Nutlin-3a | triple-receptor negative breast cancer | predicted - sensitive | detail... |
AXL positive | Dubermatinib + Olaparib | triple-receptor negative breast cancer | sensitive | detail... |
AXL positive | Bemcentinib + Olaparib | triple-receptor negative breast cancer | sensitive | detail... |
PIK3CA H1047R PTEN loss | ABT-737 + Dactolisib | triple-receptor negative breast cancer | predicted - sensitive | detail... |
PIK3CA H1047R PTEN loss | ABT-737 + Sapanisertib | triple-receptor negative breast cancer | predicted - sensitive | detail... |
PTEN loss | M2698 | triple-receptor negative breast cancer | sensitive | detail... |
PTEN A72fs | DHM25 | triple-receptor negative breast cancer | sensitive | detail... |
PTEN V275* | DHM25 | triple-receptor negative breast cancer | sensitive | detail... |
PIK3CA act mut | Bevacizumab + Doxorubicin + Everolimus | triple-receptor negative breast cancer | predicted - sensitive | detail... |
PIK3CA act mut | Bevacizumab + Doxorubicin + Temsirolimus | triple-receptor negative breast cancer | predicted - sensitive | detail... |
TP53 mutant | Doxorubicin + Seliciclib | triple-receptor negative breast cancer | predicted - sensitive | detail... |
TP53 mutant | GDC-0425 + Gemcitabine | triple-receptor negative breast cancer | predicted - sensitive | detail... |
PTEN dec exp | Ipatasertib + Paclitaxel | triple-receptor negative breast cancer | predicted - sensitive | detail... |
AXL positive | 20G7-D9 | triple-receptor negative breast cancer | sensitive | detail... |
AXL over exp | 20G7-D9 | triple-receptor negative breast cancer | sensitive | detail... |
FGFR2 - TNS1 | Infigratinib | triple-receptor negative breast cancer | sensitive | detail... |
FGFR2 - TNS1 | Buparlisib + Infigratinib | triple-receptor negative breast cancer | sensitive | detail... |
FGFR2 - TNS1 | Buparlisib | triple-receptor negative breast cancer | no benefit | detail... |
AXL positive | ADCT-601 | triple-receptor negative breast cancer | predicted - sensitive | detail... |
PTEN inact mut | Capivasertib + Paclitaxel | triple-receptor negative breast cancer | predicted - sensitive | detail... |
PTEN dec exp | Docetaxel + Ipatasertib | triple-receptor negative breast cancer | sensitive | detail... |
PTEN dec exp | Ipatasertib | triple-receptor negative breast cancer | sensitive | detail... |
PIK3CA act mut | Capivasertib + Paclitaxel | triple-receptor negative breast cancer | predicted - sensitive | detail... |
PTEN loss | Capivasertib + Paclitaxel | triple-receptor negative breast cancer | predicted - sensitive | detail... |
PIK3CA act mut | Ipatasertib + Paclitaxel | triple-receptor negative breast cancer | no benefit | detail... |
PTEN inact mut | Ipatasertib + Paclitaxel | triple-receptor negative breast cancer | no benefit | detail... |
FGFR2 positive | Alofanib | triple-receptor negative breast cancer | sensitive | detail... |
BRAF V600E | Nab-paclitaxel + Vemurafenib | triple-receptor negative breast cancer | predicted - sensitive | detail... |
ERBB3 E928A | Capecitabine + Trastuzumab | triple-receptor negative breast cancer | predicted - sensitive | detail... |
FGFR1 amp | Lucitanib | triple-receptor negative breast cancer | predicted - sensitive | detail... |
FGFR1 amp | Rogaratinib | triple-receptor negative breast cancer | no benefit | detail... |
FGFR2 amp | Futibatinib | triple-receptor negative breast cancer | predicted - sensitive | detail... |
ERBB3 over exp | Patritumab deruxtecan | triple-receptor negative breast cancer | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00576654 | Phase I | Irinotecan Veliparib | Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT00740805 | Phase I | Aldoxorubicin + Cyclophosphamide + Veliparib | Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT01116648 | Phase Ib/II | Olaparib Cediranib + Olaparib | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT01351103 | Phase I | LGK974 LGK974 + Spartalizumab | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Recruiting | USA | ITA | ESP | 1 |
NCT01391143 | Phase I | MGA271 | Safety Study of MGA271 in Refractory Cancer | Completed | USA | 0 |
NCT01562873 | Phase II | Ruxolitinib | Ruxolitinib in Patients With Breast Cancer | Terminated | USA | 0 |
NCT01587703 | Phase I | Molibresib | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers | Completed | USA | FRA | ESP | 4 |
NCT01623349 | Phase I | Alpelisib + Olaparib Buparlisib + Olaparib | Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer | Completed | USA | 0 |
NCT01639248 | Phase II | ENMD-2076 | Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC | Completed | USA | 1 |
NCT01653470 | Phase I | Carboplatin Fluorouracil + Irinotecan + Leucovorin BMS-906024 Paclitaxel | Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors | Completed | USA | CAN | BEL | 0 |
NCT01695005 | Phase I | LY3039478 | A Study of LY3039478 in Participants With Advanced Cancer | Completed | USA | FRA | ESP | DEU | 2 |
NCT01884285 | Phase I | AZD8186 Abiraterone + AZD8186 AZD8186 + Vistusertib | AZD8186 First Time In Patient Ascending Dose Study | Completed | USA | ESP | CAN | 1 |
NCT01920061 | Phase I | Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib | A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) | Completed | USA | ITA | ESP | CAN | 1 |
NCT01928394 | Phase Ib/II | Ipilimumab + Nivolumab Cobimetinib + Ipilimumab + Nivolumab Nivolumab | A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ITA | ESP | DEU | CAN | 3 |
NCT01931163 | Phase II | Everolimus | NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer | Completed | USA | 0 |
NCT01938638 | Phase I | BAY1143572 | Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer | Completed | USA | 3 |
NCT01969643 | Phase I | Ladiratuzumab vedotin Ladiratuzumab vedotin + Trastuzumab | A Safety Study of SGN-LIV1A in Breast Cancer Patients | Recruiting | USA | 0 |
NCT01982448 | Phase II | Paclitaxel Cisplatin | Cisplatin vs Paclitaxel for Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT01990209 | Phase II | Orteronel | Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) | Completed | USA | 0 |
NCT01997333 | Phase II | Glembatumumab vedotin Capecitabine | Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | 2 |
NCT01999738 | Phase I | EC1456 | Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02000882 | Phase II | Buparlisib + Capecitabine | Capecitabine + BKM120 TNBC BC Brain Met | Completed | USA | 0 |
NCT02003092 | Phase I | RX-5902 | RX-5902 Treatment of Subjects With Solid Tumors | Terminated | USA | 0 |
NCT02014337 | Phase I | Eribulin + Mifepristone | Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | Completed | USA | 0 |
NCT02032823 | Phase III | Olaparib | Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 16 |
NCT02071862 | Phase I | Everolimus + Telaglenastat Erlotinib + Telaglenastat Docetaxel + Telaglenastat Telaglenastat Paclitaxel + Telaglenastat Cabozantinib + Telaglenastat | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | Completed | USA | 0 |
NCT02078752 | Phase I | PF-06647263 | A Study Of PF-06647263 In Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02101385 | Phase II | Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer | Unknown status | USA | 0 | |
NCT02120469 | Phase I | Eribulin + Everolimus | Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer | Completed | USA | 0 |
NCT02138812 | Phase I | BAY1161909 + Paclitaxel | Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel | Terminated | USA | 0 |
NCT02157792 | Phase I | Berzosertib + Irinotecan Berzosertib + Cisplatin + Gemcitabine Berzosertib + Cisplatin + Etoposide Berzosertib + Cisplatin Berzosertib + Carboplatin + Cisplatin Berzosertib + Gemcitabine | M6620 First in Human Study | Completed | USA | 1 |
NCT02158507 | Phase I | Lapatinib + Veliparib | Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02162719 | Phase II | Ipatasertib + Paclitaxel Paclitaxel | A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Front-line Treatment for Patients With Metastatic Triple-Negative Breast Cancer | Completed | USA | ITA | FRA | ESP | BEL | 3 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT02187991 | Phase II | Paclitaxel Alisertib + Paclitaxel | Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer | Active, not recruiting | USA | 0 |
NCT02203513 | Phase II | Prexasertib | A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer | Completed | USA | 0 |
NCT02208375 | Phase Ib/II | Capivasertib + Olaparib Olaparib + Vistusertib | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian | Active, not recruiting | USA | 0 |
NCT02222922 | Phase I | Avelumab + Cofetuzumab pelidotin Fluconazole Cofetuzumab pelidotin | A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors | Completed | USA | ESP | 0 |
NCT02264678 | Phase Ib/II | Ceralasertib Carboplatin + Ceralasertib Ceralasertib + Durvalumab Ceralasertib + Olaparib | Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents | Recruiting | USA | FRA | 2 |
NCT02276443 | Phase 0 | Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative | Recruiting | USA | 0 | |
NCT02281409 | Phase Ib/II | Mogamulizumab | Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors | Completed | USA | 0 |
NCT02299635 | Phase II | Nirogacestat | A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations | Terminated | USA | ITA | ESP | 3 |
NCT02307240 | Phase I | CUDC-907 | Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors | Completed | USA | 0 |
NCT02322814 | Phase II | Cobimetinib + Paclitaxel Paclitaxel Atezolizumab + Cobimetinib + Paclitaxel Atezolizumab + Cobimetinib + Nab-paclitaxel | A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread | Completed | USA | ITA | FRA | ESP | BEL | 8 |
NCT02358200 | Phase I | Carboplatin + Paclitaxel + Talazoparib | Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer | Terminated | USA | 0 |
NCT02365662 | Phase I | ABBV-221 | A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor | Terminated | USA | ESP | 0 |
NCT02366949 | Phase I | BAY1217389 + Paclitaxel Paclitaxel | Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel | Completed | USA | 1 |
NCT02368691 | Phase II | Enobosarm | Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC) | Terminated | USA | 0 |
NCT02370238 | Phase II | Reparixin | A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer | Completed | USA | ITA | FRA | ESP | BEL | 2 |
NCT02375958 | Phase I | PCA062 | PCA062 in pCAD-positive Tumors. | Completed | USA | ITA | FRA | ESP | 2 |
NCT02393794 | Phase Ib/II | Cisplatin + Nivolumab + Romidepsin Cisplatin + Romidepsin | Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) | Active, not recruiting | USA | 0 |
NCT02401347 | Phase II | Talazoparib | Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors | Recruiting | USA | 0 |
NCT02411656 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy | Recruiting | USA | 0 |
NCT02419417 | Phase Ib/II | BMS986158 Paclitaxel | Study of BMS-986158 in Subjects With Select Advanced Solid Tumors | Completed | USA | FRA | ESP | CAN | 1 |
NCT02425891 | Phase III | Atezolizumab + Nab-paclitaxel Nab-paclitaxel | A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 32 |
NCT02427581 | Phase I | Poly ICLC | Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | Withdrawn | 0 | |
NCT02432963 | Phase I | MVAp53 + Pembrolizumab | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | Active, not recruiting | USA | 0 |
NCT02435680 | Phase II | MCS110 Carboplatin + Gemcitabine | Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) | Completed | USA | ITA | FRA | ESP | DEU | BEL | AUT | 5 |
NCT02447003 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086) | Completed | 0 | |
NCT02452424 | Phase Ib/II | Pembrolizumab + Pexidartinib | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | Terminated | USA | 0 |
NCT02456857 | Phase II | Bevacizumab Everolimus Pegylated liposomal-doxorubicin | Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative | Active, not recruiting | USA | 0 |
NCT02457910 | Phase Ib/II | Enzalutamide Enzalutamide + Taselisib | Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT02471846 | Phase I | GDC-0919 Atezolizumab | A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | 1 |
NCT02474173 | Phase I | Paclitaxel Onalespib | Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02489448 | Phase Ib/II | Durvalumab + Nab-paclitaxel Cyclophosphamide + Doxorubicin | Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer | Completed | USA | 0 |
NCT02498613 | Phase II | Cediranib + Olaparib | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT02513472 | Phase Ib/II | Eribulin + Pembrolizumab | Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) (ENHANCE-1) | Completed | USA | 0 |
NCT02528357 | Phase I | GSK3174998 Pembrolizumab | GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors | Completed | USA | FRA | CAN | 1 |
NCT02530489 | Phase II | Atezolizumab + Nab-paclitaxel | Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02531932 | Phase II | Carboplatin Everolimus | Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer | Recruiting | USA | 0 |
NCT02540291 | Phase I | E7046 | Study of E7046 in Subjects With Selected Advanced Malignancies | Terminated | USA | FRA | 0 |
NCT02543645 | Phase Ib/II | Atezolizumab + Varlilumab | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | Terminated | USA | 0 |
NCT02554812 | Phase Ib/II | Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab | A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) | Active, not recruiting | USA | FRA | CAN | 5 |
NCT02555657 | Phase III | Pembrolizumab Eribulin Gemcitabine Vinorelbine Capecitabine | Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) | Completed | 0 | |
NCT02559492 | Phase I | Epacadostat + Itacitinib Itacitinib + Parsaclisib | INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors | Terminated | USA | 0 |
NCT02574455 | Phase III | Sacituzumab govitecan-hziy Capecitabine + Eribulin + Gemcitabine + Vinorelbine | ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer (ASCENT) | Completed | USA | FRA | ESP | DEU | CAN | BEL | 1 |
NCT02575781 | Phase I | SAR428926 | A Study of SAR428926 in Patients With Advanced Solid Tumors | Completed | FRA | ESP | 1 |
NCT02580448 | Phase Ib/II | Seviteronel | A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer | Completed | USA | 0 |
NCT02593175 | Phase II | Carboplatin + Paclitaxel + Panitumumab | Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC | Recruiting | USA | 0 |
NCT02624700 | Phase II | Pemetrexed Disodium + Sorafenib | Study of Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer | Terminated | USA | 0 |
NCT02627430 | Phase I | Onalespib + Talazoparib | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer | Withdrawn | 0 | |
NCT02628535 | Phase I | Obrindatamab | Safety Study of MGD009 in B7-H3-expressing Tumors | Terminated | USA | CAN | 1 |
NCT02630368 | Phase Ib/II | Avelumab + Cyclophosphamide + JX-594 Cyclophosphamide + JX-594 Cyclophosphamide | A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) (METROmaJX) | Recruiting | FRA | 0 |
NCT02632448 | Phase Ib/II | Gemcitabine + LY2880070 LY2880070 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | Completed | USA | CAN | 0 |
NCT02637375 | Phase I | Cyclophosphamide + Doxorubicin + Paclitaxel Ganetespib | A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer | Withdrawn | 0 | |
NCT02644369 | Phase II | Pembrolizumab | Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (INSPIRE) | Active, not recruiting | CAN | 0 |
NCT02646748 | Phase I | Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | Completed | USA | 0 |
NCT02648477 | Phase II | Letrozole + Pembrolizumab Exemestane + Pembrolizumab Anastrozole + Pembrolizumab Doxorubicin + Pembrolizumab | Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT02657889 | Phase Ib/II | Niraparib + Pembrolizumab | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (TOPACIO) | Completed | USA | 0 |
NCT02658214 | Phase I | Cisplatin + Durvalumab + Fluorouracil + Tremelimumab Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab Carboplatin + Durvalumab + Gemcitabine + Tremelimumab | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | Completed | 2 | |
NCT02660034 | Phase I | Pamiparib + Tislelizumab | The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors | Completed | USA | FRA | ESP | 3 |
NCT02672475 | Phase I | Galunisertib + Paclitaxel | Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02676986 | Phase II | Enzalutamide + Exemestane Exemestane Enzalutamide | Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer (ARB) | Unknown status | USA | ESP | DEU | 2 |
NCT02689427 | Phase II | Enzalutamide + Paclitaxel | Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer | Recruiting | USA | 0 |
NCT02698176 | Phase I | Birabresib | A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006) | Terminated | 0 | |
NCT02706392 | Phase I | Cyclophosphamide + Fludarabine + ROR1 CAR-T cells | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | Terminated | USA | 0 |
NCT02708680 | Phase Ib/II | Atezolizumab Atezolizumab + Entinostat | Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In | Completed | USA | 1 |
NCT02719691 | Phase I | Alisertib + Sapanisertib | Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer | Completed | USA | 0 |
NCT02720185 | Phase II | Dasatinib | Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR | Terminated | USA | 0 |
NCT02730130 | Phase II | Pembrolizumab | Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients | Active, not recruiting | USA | 0 |
NCT02734290 | Phase Ib/II | Capecitabine + Pembrolizumab Paclitaxel + Pembrolizumab | Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer | Active, not recruiting | USA | 0 |
NCT02750358 | Phase II | Enzalutamide | Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02752685 | Phase II | Nab-paclitaxel + Pembrolizumab | Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT02755272 | Phase II | Pembrolizumab Carboplatin + Gemcitabine | A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT02760797 | Phase I | Emactuzumab + Selicrelumab | A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors | Completed | USA | FRA | BEL | 0 |
NCT02761694 | Phase I | ARQ 751 + Paclitaxel ARQ 751 ARQ 751 + Fulvestrant | ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations | Terminated | USA | 0 |
NCT02762981 | Phase Ib/II | Nab-paclitaxel + Relacorilant | Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors | Completed | USA | 0 |
NCT02768701 | Phase II | Cyclophosphamide + Pembrolizumab | Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02783300 | Phase I | GSK3326595 | Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) | Active, not recruiting | USA | FRA | CAN | 1 |
NCT02784795 | Phase I | Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3023414 + LY3039478 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | 1 |
NCT02788981 | Phase II | Mifepristone + Nab-paclitaxel Nab-paclitaxel | Abraxane With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02807844 | Phase Ib/II | MCS110 + Spartalizumab | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | Completed | USA | ITA | FRA | ESP | DEU | BEL | 5 |
NCT02819518 | Phase III | Paclitaxel Pembrolizumab Nab-paclitaxel Carboplatin + Gemcitabine | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) | Active, not recruiting | 0 | |
NCT02824042 | Phase I | Anetumab ravtansine + Itraconazole Anetumab ravtansine | Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole | Completed | USA | FRA | ESP | BEL | 2 |
NCT02826434 | Phase I | Durvalumab + Poly ICLC + PVX-410 | Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02829723 | Phase Ib/II | BLZ945 BLZ945 + Spartalizumab | Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors | Active, not recruiting | USA | ITA | ESP | 5 |
NCT02834247 | Phase I | Mivavotinib + Nivolumab | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors | Terminated | USA | ITA | ESP | 1 |
NCT02834403 | Phase Ib/II | Pegfilgrastim Docetaxel + L-NMMA | L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients | Completed | USA | 0 |
NCT02876107 | Phase II | Cyclophosphamide + Doxorubicin Carboplatin + Paclitaxel + Panitumumab Carboplatin + Paclitaxel | Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02876302 | Phase II | Cyclophosphamide + Doxorubicin + Paclitaxel + Ruxolitinib | Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer | Active, not recruiting | USA | 0 |
NCT02880371 | Phase Ib/II | ARRY-382 + Pembrolizumab | A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02883062 | Phase II | Carboplatin + Paclitaxel Atezolizumab + Carboplatin + Paclitaxel | Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02890069 | Phase I | LCL161 + Spartalizumab Everolimus + Spartalizumab Panobinostat + Spartalizumab | A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | Completed | USA | ESP | DEU | 4 |
NCT02898207 | Phase I | Olaparib + Onalespib | Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02900664 | Phase I | Nazartinib + Spartalizumab CJM112 + Spartalizumab Spartalizumab + Trametinib Canakinumab + Spartalizumab Canakinumab | A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib) | Completed | USA | ITA | FRA | ESP | CAN | BEL | 3 |
NCT02926690 | Phase I | OTS167 | Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT02929576 | Phase III | Paclitaxel Enzalutamide + Paclitaxel Enzalutamide | Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer (ENDEAR) | Withdrawn | USA | 0 |
NCT02936102 | Phase I | FAZ053 FAZ053 + Spartalizumab | A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. | Active, not recruiting | USA | ITA | FRA | ESP | CAN | 4 |
NCT02938442 | Phase II | Montanide ISA 51 + P10s-PADRE | Vaccination of Triple Negative Breast Cancer Patients | Recruiting | USA | 0 |
NCT02947165 | Phase I | NIS793 + Spartalizumab NIS793 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | Completed | USA | ITA | DEU | CAN | AUT | 4 |
NCT02950064 | Phase I | BTP-114 | A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations | Unknown status | USA | 0 |
NCT02952248 | Phase I | BI 754091 | A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours | Active, not recruiting | USA | CAN | 1 |
NCT02954874 | Phase III | Pembrolizumab | Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | Active, not recruiting | USA | CAN | 1 |
NCT02971761 | Phase II | Enobosarm + Pembrolizumab | Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02977156 | Phase I | Ipilimumab + JX-594 | Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. (ISI-JX) | Completed | FRA | 0 |
NCT02977468 | Phase I | Pembrolizumab | Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer (Pembro/IORT) | Recruiting | USA | 0 |
NCT02978716 | Phase II | Carboplatin + Gemcitabine Carboplatin + Gemcitabine + Trilaciclib | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) | Terminated | USA | BEL | 6 |
NCT02981303 | Phase II | Pembrolizumab + PGG beta-glucan | Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer | Completed | USA | 0 |
NCT02984683 | Phase II | SAR566658 | Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer | Terminated | ITA | ESP | BEL | 2 |
NCT02985658 | Phase I | Cisplatin Veliparib Vinorelbine | Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer | No longer available | USA | 0 |
NCT02996825 | Phase I | Gemcitabine + Mirvetuximab Soravtansine | Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03004183 | Phase II | Pembrolizumab AdV-tk + Valacyclovir | SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC | Active, not recruiting | USA | 0 |
NCT03012100 | Phase II | Cyclophosphamide + Sargramostim Cyclophosphamide + FR alpha peptide vaccine + Sargramostim | Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT03012230 | Phase I | Pembrolizumab + Ruxolitinib | Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT03012477 | Phase II | Adavosertib + Cisplatin | CISPLATIN + AZD-1775 In Breast Cancer | Completed | USA | 0 |
NCT03018405 | Phase Ib/II | NKR-2 cells | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) | Unknown status | USA | BEL | 0 |
NCT03036488 | Phase III | Cyclophosphamide + Epirubicin Cyclophosphamide + Doxorubicin Pembrolizumab Carboplatin + Paclitaxel | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | 15 |
NCT03044730 | Phase II | Capecitabine + Pembrolizumab | Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery | Unknown status | USA | 0 |
NCT03076372 | Phase I | MM-310 | A Study Evaluating MM-310 in Patients With Solid Tumors | Unknown status | USA | 0 |
NCT03090165 | Phase Ib/II | Bicalutamide + Ribociclib | Ribociclib and Bicalutamide in AR+ TNBC | Active, not recruiting | USA | 0 |
NCT03095352 | Phase II | Carboplatin + Pembrolizumab + Trastuzumab Carboplatin Carboplatin + Trastuzumab Carboplatin + Pembrolizumab | Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease | Recruiting | USA | 0 |
NCT03096054 | Phase I | LY3143921 | A CR-UK Phase I Trial of LY3143921 | Active, not recruiting | 1 | |
NCT03098550 | Phase Ib/II | Daratumumab + Nivolumab | A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread | Completed | USA | ITA | FRA | ESP | DEU | CAN | 3 |
NCT03102320 | Phase I | Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin | Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) | Completed | USA | ITA | FRA | ESP | CAN | BEL | 6 |
NCT03106077 | Phase II | Mirvetuximab Soravtansine | Mirvetuximab Soravtansine in Localized Triple-Negative Breast Cancer (TNBC) | Completed | USA | 0 |
NCT03106415 | Phase Ib/II | Binimetinib + Pembrolizumab | Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03121352 | Phase II | Carboplatin + Nab-paclitaxel + Pembrolizumab | Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03125902 | Phase III | Paclitaxel Atezolizumab + Paclitaxel | A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | 18 |
NCT03130439 | Phase II | Abemaciclib | Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT03150810 | Phase Ib/II | Pamiparib + Temozolomide | Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ESP | 2 |
NCT03167619 | Phase II | Durvalumab + Olaparib Olaparib | Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) (DORA) | Active, not recruiting | USA | 0 |
NCT03184558 | Phase II | Bemcentinib + Pembrolizumab | BGB324 in Combination With Pembrolizumab in Patients With TNBC | Terminated | USA | ESP | 2 |
NCT03193853 | Phase II | Cisplatin + Nab-paclitaxel Sapanisertib + Serabelisib | TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03197935 | Phase III | Pegfilgrastim Doxorubicin Atezolizumab Filgrastim Nab-paclitaxel Cyclophosphamide | A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031) | Active, not recruiting | USA | ITA | ESP | DEU | CAN | BEL | 7 |
NCT03199040 | Phase I | Durvalumab | Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy | Active, not recruiting | USA | 0 |
NCT03206203 | Phase II | Atezolizumab + Carboplatin Carboplatin | Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03207867 | Phase II | PBF-509 + Spartalizumab | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | AUT | 8 |
NCT03213041 | Phase II | Carboplatin + Pembrolizumab | Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT03221400 | Phase Ib/II | STA-8666 | PEN-866 in Patients With Advanced Solid Malignancies | Recruiting | USA | 0 |
NCT03225547 | Phase II | Mifepristone + Pembrolizumab | Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03243331 | Phase I | Cofetuzumab pelidotin + Gedatolisib | An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer | Completed | USA | 0 |
NCT03256344 | Phase I | Atezolizumab + Talimogene laherparepvec | Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases | Completed | USA | ESP | DEU | BEL | 2 |
NCT03281954 | Phase III | Atezolizumab | Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo | Active, not recruiting | USA | CAN | 0 |
NCT03289962 | Phase I | RO7198457 Atezolizumab + RO7198457 | A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | Active, not recruiting | USA | ESP | DEU | CAN | BEL | 3 |
NCT03292172 | Phase I | Atezolizumab + TEN-010 | A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer | Terminated | USA | CAN | 3 |
NCT03310957 | Phase Ib/II | Ladiratuzumab vedotin + Pembrolizumab | Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer | Recruiting | USA | ESP | DEU | 1 |
NCT03316586 | Phase II | Cabozantinib + Nivolumab | A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer | Completed | USA | 0 |
NCT03316794 | Phase I | SC-005 | A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC) | Terminated | USA | 0 |
NCT03318562 | Phase II | Tomivosertib | A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC | Terminated | USA | 0 |
NCT03330405 | Phase II | Avelumab + Talazoparib | Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors | Active, not recruiting | USA | CAN | BEL | 6 |
NCT03330847 | Phase II | Adavosertib + Olaparib Olaparib Ceralasertib + Olaparib | To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 8 |
NCT03337724 | Phase II | Ipatasertib + Paclitaxel Paclitaxel | A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (IPATunity130) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 23 |
NCT03356860 | Phase Ib/II | Cyclophosphamide + Durvalumab + Epirubicin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel | Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. (B-IMMUNE) | Active, not recruiting | BEL | 0 |
NCT03361800 | Phase I | Entinostat | Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC | Terminated | USA | 0 |
NCT03362060 | Phase I | Pembrolizumab + PVX-410 | PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03363893 | Phase Ib/II | ICEC0942 Fulvestrant + ICEC0942 | Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies | Active, not recruiting | USA | 1 |
NCT03366844 | Phase Ib/II | Pembrolizumab | Breast Cancer Study of Preoperative Pembrolizumab + Radiation | Active, not recruiting | USA | 0 |
NCT03371017 | Phase III | Atezolizumab + Capecitabine + Carboplatin + Gemcitabine Capecitabine + Carboplatin + Gemcitabine | A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer (IMpassion132) | Recruiting | USA | ITA | FRA | ESP | DEU | 25 |
NCT03383679 | Phase II | Darolutamide Capecitabine | Study on Androgen Receptor and Triple Negative Breast Cancer (START) | Active, not recruiting | FRA | 0 |
NCT03387085 | Phase Ib/II | ETBX-051 Aldoxorubicin ETBX-061 Cisplatin Cyclophosphamide haNK cells GI-4000 Bevacizumab ALT-803 Fluorouracil ETBX-011 Oxaliplatin Capecitabine Leucovorin GI-6301 Nab-paclitaxel Avelumab GI-6207 | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. | Active, not recruiting | USA | 0 |
NCT03414684 | Phase II | Carboplatin + Nivolumab Carboplatin | Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03424005 | Phase Ib/II | Atezolizumab + Bevacizumab + Selicrelumab Atezolizumab + RO6874281 Atezolizumab + Bevacizumab Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + Eribulin Capecitabine Atezolizumab Atezolizumab + Bevacizumab + Cobimetinib Atezolizumab + Capecitabine Atezolizumab + Ipatasertib Atezolizumab + Ladiratuzumab vedotin | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC) (Morpheus-TNBC) | Recruiting | USA | FRA | ESP | DEU | 4 |
NCT03435640 | Phase Ib/II | NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 | A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies | Terminated | USA | 0 |
NCT03454451 | Phase I | CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | Active, not recruiting | USA | 1 |
NCT03464942 | Phase II | Atezolizumab | Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer (AZTEC) | Active, not recruiting | 1 | |
NCT03483012 | Phase II | Atezolizumab | Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis | Active, not recruiting | USA | 0 |
NCT03487666 | Phase II | Capecitabine + Nivolumab Capecitabine Nivolumab | OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease | Active, not recruiting | USA | 0 |
NCT03498716 | Phase III | Atezolizumab + Cyclophosphamide + Epirubicin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel Cyclophosphamide + Doxorubicin + Paclitaxel Atezolizumab + Cyclophosphamide + Doxorubicin + Paclitaxel | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMpassion030) | Recruiting | USA | ITA | FRA | ESP | DEU | BEL | AUT | 24 |
NCT03499899 | Phase II | Carboplatin + Ieramilimab Carboplatin + Ieramilimab + Spartalizumab Ieramilimab + Spartalizumab | A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | 10 |
NCT03504488 | Phase Ib/II | BA3021 | CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors | Recruiting | USA | 2 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Active, not recruiting | USA | 0 |
NCT03519178 | Phase II | PF-06873600 | A Study of PF-06873600 in People With Cancer | Recruiting | USA | CAN | 4 |
NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03542175 | Phase I | Rucaparib | A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy | Recruiting | USA | 0 |
NCT03544125 | Phase I | Durvalumab + Olaparib | Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer | Completed | USA | 0 |
NCT03546686 | Phase II | Ipilimumab + Nivolumab | Peri-Operative Ipilimumab+Nivolumab and Cryoablation in Women With Triple-negative Breast Cancer | Recruiting | USA | 0 |
NCT03554109 | Phase II | Aldoxorubicin + ALT-803 + Avelumab + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel Cyclophosphamide + Doxorubicin + Paclitaxel | QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine | Withdrawn | USA | 0 |
NCT03562637 | Phase III | Adagloxad simolenin + OBI-821 | Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC | Recruiting | USA | 10 |
NCT03564782 | Phase I | PVSRIPO | Examining Bioactivity of PVSRIPO in Invasive Breast Cancer | Recruiting | USA | 0 |
NCT03567720 | Phase II | Pembrolizumab + Tavokinogene telseplasmid Nab-paclitaxel + Pembrolizumab + Tavokinogene telseplasmid | Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC | Recruiting | USA | 1 |
NCT03579472 | Phase I | Eribulin + M7824 | M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT03599453 | Phase I | Celecoxib + Interferon alpha-2b + Pembrolizumab + Rintatolimod | Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03606967 | Phase II | Durvalumab + Nab-paclitaxel + Poly ICLC + Tremelimumab + TSMA-based SLP vaccine Nab-paclitaxel Carboplatin + Gemcitabine Durvalumab + Nab-paclitaxel + Tremelimumab | Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT03616886 | Phase Ib/II | Carboplatin + Durvalumab + Oleclumab + Paclitaxel Carboplatin + Durvalumab + Paclitaxel | Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC (SYNERGY) | Active, not recruiting | FRA | BEL | 0 |
NCT03620643 | Phase II | Crizotinib Crizotinib + Fulvestrant | Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours (ROLo) | Recruiting | 1 | |
NCT03621982 | Phase I | Camidanlumab Tesirine | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Recruiting | USA | BEL | 1 |
NCT03639948 | Phase II | Carboplatin + Docetaxel + Pegfilgrastim + Pembrolizumab | Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer (NeoPACT) | Active, not recruiting | USA | 0 |
NCT03644589 | Phase II | Cisplatin + Pembrolizumab | Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer | Withdrawn | USA | 0 |
NCT03654547 | Phase I | TT-00420 | Safety of TT-00420 Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer | Active, not recruiting | USA | 1 |
NCT03661632 | Phase Ib/II | BMS-986310 + Nivolumab | An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | CAN | BEL | 0 |
NCT03665285 | Phase Ib/II | NC318 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT03667716 | Phase I | COM701 COM701 + Nivolumab | COM701 in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT03674242 | Phase II | Carboplatin + Gemcitabine Carboplatin + Eryaspase + Gemcitabine | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 1st Line Treatment of TNBC (TRYbeCA-2) | Terminated | ESP | BEL | 1 |
NCT03674567 | Phase Ib/II | FLX475 + Pembrolizumab FLX475 | Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab | Recruiting | USA | 5 |
NCT03674827 | Phase I | PF-06936308 | A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC | Terminated | USA | 0 |
NCT03681951 | Phase Ib/II | GSK3145095 GSK3145095 + Pembrolizumab | First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors | Terminated | USA | 0 |
NCT03694249 | Phase II | Ifetroban sodium | Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence | Recruiting | USA | 0 |
NCT03700294 | Phase I | ADCT-601 | Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors | Terminated | USA | 0 |
NCT03709446 | Phase Ib/II | Leflunomide | Leflunomide in Previously Treated Metastatic Triple Negative Cancers | Recruiting | USA | 0 |
NCT03719326 | Phase I | AB928 + IPI-549 + Pegylated liposomal-doxorubicin AB928 + Pegylated liposomal-doxorubicin | A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies | Completed | USA | 1 |
NCT03733119 | Phase II | ONC201 | ONC201 With and Without Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer | Terminated | USA | 0 |
NCT03740893 | Phase II | Olaparib Ceralasertib Durvalumab | PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer (PHOENIX) | Recruiting | 1 | |
NCT03742102 | Phase Ib/II | Durvalumab + Oleclumab + Paclitaxel Durvalumab + Trastuzumab deruxtecan Durvalumab + Paclitaxel Capivasertib + Durvalumab + Paclitaxel | A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (BEGONIA) | Active, not recruiting | USA | CAN | 4 |
NCT03742349 | Phase I | Canakinumab + Ieramilimab + Spartalizumab Ieramilimab + MCS110 + Spartalizumab Capmatinib + Ieramilimab + Spartalizumab Ieramilimab + PBF-509 + Spartalizumab | Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). | Active, not recruiting | USA | ITA | ESP | 6 |
NCT03752398 | Phase I | XmAb23104 | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Recruiting | USA | 0 |
NCT03761914 | Phase Ib/II | Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | Active, not recruiting | USA | 0 |
NCT03775850 | Phase Ib/II | EDP1503 EDP1503 + Pembrolizumab | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | Completed | USA | CAN | 0 |
NCT03797326 | Phase II | Lenvatinib + Pembrolizumab | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | 11 |
NCT03800836 | Phase I | Atezolizumab + Ipatasertib + Paclitaxel Atezolizumab + Ipatasertib + Nab-paclitaxel | A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer | Completed | USA | FRA | ESP | 2 |
NCT03801369 | Phase II | Durvalumab + Olaparib | Olaparib and Durvalumab to Treat Patients With Metastatic Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT03802604 | Phase I | Atezolizumab + Talimogene laherparepvec | Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer (PROMETEO) | Active, not recruiting | ESP | 0 |
NCT03812393 | Phase II | Carboplatin + Neratinib + Paclitaxel Neratinib | Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast (FACT-2) | Recruiting | USA | 0 |
NCT03818685 | Phase II | Ipilimumab + Nivolumab Capecitabine | Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease (BreastImmune03) | Active, not recruiting | FRA | 0 |
NCT03821935 | Phase I | ABBV-151 ABBV-151 + ABBV-181 | Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | CAN | BEL | 6 |
NCT03829501 | Phase Ib/II | Atezolizumab + KY1044 KY1044 | Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer | Recruiting | USA | ITA | 2 |
NCT03838367 | Phase Ib/II | Carboplatin + Leronlimab | Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC | Active, not recruiting | USA | 0 |
NCT03849469 | Phase I | Pembrolizumab + XmAb22841 XmAb22841 | A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) | Active, not recruiting | USA | 0 |
NCT03853707 | Phase Ib/II | Carboplatin + Ipatasertib + Paclitaxel Carboplatin + Ipatasertib Atezolizumab + Capecitabine + Ipatasertib | Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer | Suspended | USA | 0 |
NCT03861403 | Phase Ib/II | Avelumab + Cyclophosphamide + TRX518 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | Terminated | USA | 0 |
NCT03872388 | Phase II | Atorvastatin + Capecitabine Capecitabine | Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy | Recruiting | USA | 0 |
NCT03872505 | Phase II | Carboplatin + Durvalumab + Paclitaxel | Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer (PANDoRA) | Withdrawn | USA | 0 |
NCT03875313 | Phase Ib/II | Talazoparib + Telaglenastat | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | Terminated | USA | 0 |
NCT03891953 | Phase I | DKY709 DKY709 + Spartalizumab | Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | Recruiting | USA | ESP | DEU | 3 |
NCT03893955 | Phase I | ABBV-368 + ABBV-927 + Nab-paclitaxel ABBV-368 + ABBV-927 ABBV-181 + ABBV-368 + ABBV-927 ABBV-181 + ABBV-927 + Carboplatin ABBV-927 + Carboplatin ABBV-368 + ABBV-927 + Carboplatin | A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | 3 |
NCT03901469 | Phase II | Talazoparib + ZEN-3694 | A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC) | Recruiting | USA | ESP | BEL | 0 |
NCT03911453 | Phase I | Rucaparib | Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors | Active, not recruiting | USA | 0 |
NCT03911973 | Phase Ib/II | Gedatolisib + Talazoparib | Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers | Recruiting | USA | 0 |
NCT03915678 | Phase II | Atezolizumab + BDB001 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors (AGADIR) | Recruiting | FRA | 0 |
NCT03917381 | Phase Ib/II | GEN1046 | GEN1046 Safety Trial in Patients With Malignant Solid Tumors | Recruiting | USA | ITA | ESP | 4 |
NCT03941730 | Phase II | Estradiol | Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT03945721 | Phase I | Niraparib | A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients | Recruiting | USA | 0 |
NCT03950570 | Phase I | ORIN1001 + Paclitaxel ORIN1001 | ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT03952325 | Phase II | Pembrolizumab + Tesetaxel Nivolumab + Tesetaxel Tesetaxel Atezolizumab + Tesetaxel | Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Patients With HER2 Negative MBC (CONTESSA TRIO) | Terminated | USA | 2 |
NCT03961698 | Phase II | Atezolizumab + Bevacizumab + IPI-549 Atezolizumab + IPI-549 + Nab-paclitaxel | Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3) (MARIO-3) | Active, not recruiting | USA | 0 |
NCT03971409 | Phase II | Avelumab + PF-04518600 Avelumab + Utomilumab Avelumab + Binimetinib | Avelumab With Binimetinib, Utomilumab, or Anti-OX40 Antibody PF-04518600 in Treating Triple Negative Breast Cancer (InCITe) | Recruiting | USA | 0 |
NCT03977467 | Phase II | Atezolizumab + Carboplatin Atezolizumab + Tiragolumab Atezolizumab + Cisplatin Atezolizumab + Bevacizumab + Carboplatin Atezolizumab + Bevacizumab + Cisplatin | Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor | Recruiting | USA | 0 |
NCT03979508 | Phase II | Abemaciclib | Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT03990233 | Phase I | Effi-DEM BI 754091 + Effi-DEM | A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours | Recruiting | FRA | BEL | 0 |
NCT03990896 | Phase II | Talazoparib | Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial | Recruiting | USA | 0 |
NCT03992131 | Phase Ib/II | Lucitanib + Rucaparib Rucaparib + Sacituzumab govitecan-hziy | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR) | Terminated | USA | 0 |
NCT03997123 | Phase III | Paclitaxel Capivasertib + Paclitaxel | Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC (CapItello290) | Recruiting | USA | FRA | ESP | CAN | 27 |
NCT03997968 | Phase Ib/II | CYT01B | A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04024436 | Phase II | Fulvestrant + Futibatinib Futibatinib | A Study of TAS-120 in Patients With Metastatic Breast Cancer | Recruiting | USA | ITA | FRA | ESP | CAN | 2 |
NCT04024800 | Phase II | AE37 + Pembrolizumab | Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer (NSABP FB-14) | Active, not recruiting | USA | 0 |
NCT04032080 | Phase II | Prexasertib LY3023414 | Treatment With Oral LY3023414 To Inhibit Homologous Recombination Followed By Prexasertib (ExIST) | Active, not recruiting | USA | 0 |
NCT04039230 | Phase Ib/II | Sacituzumab govitecan-hziy + Talazoparib | Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. | Recruiting | USA | 0 |
NCT04041128 | Phase I | Olaparib | PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer | Active, not recruiting | USA | 0 |
NCT04052555 | Phase I | Berzosertib | Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer | Recruiting | USA | 0 |
NCT04060342 | Phase Ib/II | GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | Terminated | USA | 1 |
NCT04081389 | Phase I | Celecoxib + Cyclophosphamide + Doxorubicin + Interferon alpha-2b + Paclitaxel + Rintatolimod | Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer | Suspended | USA | 0 |
NCT04095689 | Phase II | Cyclophosphamide + Docetaxel + Doxorubicin + IL-12 gene + L-NMMA + Pembrolizumab | TAC Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy and L-NMMA in Triple Negative Breast Cancer | Suspended | USA | 0 |
NCT04096638 | Phase I | Nivolumab + SB 11285 SB 11285 | Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04102618 | Phase I | Atezolizumab + Pelareorep Atezolizumab + Pelareorep + Trastuzumab Letrozole + Pelareorep Atezolizumab + Letrozole + Pelareorep | A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (AWARE-1) | Recruiting | ESP | 0 |
NCT04111510 | Phase II | LN-145 | Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT04115306 | Phase I | PMD-026 | Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT04123704 | Phase II | Sitravatinib | Sitravatinib in Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT04148911 | Phase III | Atezolizumab + Nab-paclitaxel | A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer (EL1SSAR) | Active, not recruiting | ITA | FRA | ESP | 10 |
NCT04152499 | Phase Ib/II | SKB264 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264) | Recruiting | USA | 1 |
NCT04176848 | Phase II | CFI-400945 + Durvalumab | CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer | Active, not recruiting | CAN | 0 |
NCT04177108 | Phase III | Ipatasertib + Paclitaxel Atezolizumab + Paclitaxel Atezolizumab + Ipatasertib + Paclitaxel Paclitaxel | A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer. | Active, not recruiting | USA | ITA | FRA | ESP | CAN | BEL | AUT | 30 |
NCT04185311 | Phase I | Ipilimumab + Nivolumab + Talimogene laherparepvec | Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted | Active, not recruiting | USA | 0 |
NCT04191135 | Phase II | Carboplatin + Gemcitabine + Pembrolizumab Carboplatin + Gemcitabine + Olaparib + Pembrolizumab | Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) | Active, not recruiting | USA | FRA | ESP | DEU | CAN | 10 |
NCT04216472 | Phase II | Alpelisib + Nab-paclitaxel | Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations | Unknown status | USA | 0 |
NCT04225117 | Phase II | Enfortumab vedotin-ejfv | A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | Recruiting | USA | CAN | 1 |
NCT04230109 | Phase II | Sacituzumab govitecan-hziy | Sacituzumab Govitecan In TNBC (NeoSTAR) | Active, not recruiting | USA | 0 |
NCT04243616 | Phase II | Carboplatin + Cemiplimab + Cyclophosphamide + Doxorubicin + Paclitaxel Cemiplimab + Cyclophosphamide + Doxorubicin + Paclitaxel | Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer | Recruiting | USA | 0 |
NCT04249167 | Phase I | Atezolizumab + Nab-paclitaxel | Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer | Withdrawn | 0 | |
NCT04251533 | Phase III | Alpelisib + Nab-paclitaxel Nab-paclitaxel | Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss | Recruiting | USA | ITA | FRA | ESP | DEU | AUT | 29 |
NCT04260802 | Phase Ib/II | OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | Recruiting | CAN | 0 |
NCT04265872 | Phase I | Bortezomib + Cisplatin + Pembrolizumab | Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC | Recruiting | USA | 0 |
NCT04282018 | Phase Ib/II | BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | Recruiting | 2 | |
NCT04282044 | Phase I | CRX100 | Study of CRX100 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04300556 | Phase Ib/II | MORAb-202 | A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FR alpha)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | Recruiting | USA | 1 |
NCT04301011 | Phase Ib/II | TBio-6517 Pembrolizumab + TBio-6517 | Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors (RAPTOR) | Recruiting | USA | CAN | 1 |
NCT04315233 | Phase I | Belinostat + Ribociclib | Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics (CHARGE) | Recruiting | USA | 0 |
NCT04331067 | Phase Ib/II | Cabiralizumab + Carboplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Paclitaxel | Cabiralizumab in Combination With Nivolumab and Neoadjuvant Chemotherapy in Patients With Localized Triple-negative Breast Cancer | Recruiting | USA | 0 |
NCT04332653 | Phase Ib/II | NT-I7 + Pembrolizumab | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (KEYNOTE A60) | Recruiting | USA | 0 |
NCT04338685 | Phase I | RO7119929 + Tocilizumab | A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases | Active, not recruiting | USA | ESP | 4 |
NCT04344795 | Phase I | TPST-1495 Pembrolizumab + TPST-1495 | Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors | Recruiting | USA | 0 |
NCT04345913 | Phase Ib/II | Eribulin Copanlisib + Eribulin | Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer | Suspended | USA | 0 |
NCT04348747 | Phase II | Anti-HER2/HER3 DC vaccine + Celecoxib + Interferon alpha-2b + Pembrolizumab + Rintatolimod Anti-HER2/HER3 DC vaccine + Celecoxib + Interferon alpha-2b + Rintatolimod | Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer | Recruiting | USA | 0 |
NCT04360941 | Phase I | Avelumab + Palbociclib | PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer (PAveMenT) | Recruiting | 1 | |
NCT04373031 | Phase II | Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Cyclophosphamide + Doxorubicin + IRX-2 + Paclitaxel + Pembrolizumab | Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT04408118 | Phase II | Atezolizumab + Bevacizumab + Paclitaxel | First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin) in mTNBC (ATRACTIB) | Recruiting | ITA | FRA | ESP | DEU | 1 |
NCT04423029 | Phase Ib/II | DF6002 DF6002 + Nivolumab | A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | 0 |
NCT04424641 | Phase Ib/II | GEN1044 | A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors | Terminated | USA | ESP | 2 |
NCT04427293 | Phase I | Lenvatinib + Pembrolizumab | Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) | Recruiting | USA | 0 |
NCT04429542 | Phase I | BCA101 BCA101 + Pembrolizumab | Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT04432857 | Phase I | E7046 + Pembrolizumab | AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | Recruiting | USA | FRA | 0 |
NCT04434040 | Phase II | Atezolizumab + Ipatasertib | Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC | Recruiting | USA | 0 |
NCT04434482 | Phase I | Senaparib + Temozolomide | IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer | Recruiting | 3 | |
NCT04434560 | Phase II | Ipilimumab + Nivolumab | Neoadjuvant Immunotherapy in Brain Metastases | Terminated | USA | 0 |
NCT04441099 | Phase Ib/II | NBE-002 | NBE-002 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04443348 | Phase II | Pembrolizumab Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab | Pre-op Pembro + Radiation Therapy in Breast Cancer | Recruiting | USA | 0 |
NCT04445844 | Phase II | Pelareorep + Retifanlimab | INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study | Recruiting | USA | 0 |
NCT04454528 | Phase Ib/II | Pembrolizumab | BreastVax: Radiation Boost to Enhance Effectiveness of Immune Checkpoint Blockade Therapy in Operable Breast Cancer | Recruiting | USA | 0 |
NCT04461600 | Phase II | BMS-906024 | A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer (TENACITY) | Active, not recruiting | USA | ESP | BEL | 2 |
NCT04464174 | Phase II | Eribulin + Ipatasertib Capecitabine + Ipatasertib Carboplatin + Gemcitabine + Ipatasertib | Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer (PATHFINDER) | Recruiting | ESP | 1 |
NCT04468061 | Phase II | Sacituzumab govitecan-hziy Pembrolizumab + Sacituzumab govitecan-hziy | Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | Recruiting | USA | 0 |
NCT04489940 | Phase II | M7824 | Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer | Completed | USA | ITA | FRA | ESP | BEL | 1 |
NCT04491942 | Phase I | BAY1895344 + Cisplatin BAY1895344 + Cisplatin + Gemcitabine | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | Recruiting | USA | 0 |
NCT04494958 | Phase Ib/II | Binimetinib + Palbociclib | Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer (PALBOBIN) | Recruiting | ESP | 0 |
NCT04504669 | Phase I | AZD8701 + Durvalumab AZD8701 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | Recruiting | USA | FRA | ESP | CAN | 0 |
NCT04514484 | Phase I | Cabozantinib + Nivolumab | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | Recruiting | USA | 0 |
NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |
NCT04521621 | Phase Ib/II | Coxsackievirus A21 + Pembrolizumab | A Study of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | 8 |
NCT04553133 | Phase II | PF-07104091 Letrozole + Palbociclib + PF-07104091 Palbociclib + PF-07104091 | PF-07104091 as a Single Agent and in Combination Therapy | Recruiting | USA | 0 |
NCT04561362 | Phase Ib/II | BT8009 BT8009 + Nivolumab | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumors Malignancies | Recruiting | USA | ITA | FRA | ESP | CAN | 1 |
NCT04574583 | Phase Ib/II | FPV-CV301 + M7824 + MVA-BN-CV301 + SX-682 | Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) | Active, not recruiting | USA | 0 |
NCT04577963 | Phase Ib/II | Fruquintinib + Tislelizumab | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT04580485 | Phase I | INCB106385 + Retifanlimab INCB106385 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | Recruiting | USA | ITA | FRA | ESP | BEL | 1 |
NCT04584112 | Phase I | Atezolizumab + Cyclophosphamide + Doxorubicin + Pegfilgrastim + Tiragolumab Atezolizumab + Cyclophosphamide + Doxorubicin + Sargramostim + Tiragolumab Atezolizumab + Nab-paclitaxel + Tiragolumab Atezolizumab + Cyclophosphamide + Doxorubicin + Filgrastim + Tiragolumab | A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer | Active, not recruiting | USA | ESP | DEU | 5 |
NCT04592653 | Phase II | ALKS 4230 + Pembrolizumab | A Study of ALKS 4230 on the Tumor Microenvironment (ARTISTRY-3) | Recruiting | USA | 0 |
NCT04596150 | Phase II | CX-2009 CX-072 + CX-2009 | Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer | Active, not recruiting | USA | ESP | 1 |
NCT04622774 | Phase I | IMGC936 | First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04639245 | Phase Ib/II | MAGE-A1-specific TCR cells + unspecified PD-1 antibody Cyclophosphamide + Fludarabine Atezolizumab + MAGE-A1-specific TCR cells MAGE-A1-specific TCR cells | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | Suspended | USA | 0 |
NCT04682431 | Phase I | Pembrolizumab + PY159 PY159 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04683679 | Phase II | Olaparib + Pembrolizumab Pembrolizumab | A Study of Radiation Therapy With Pembrolizumab and Olaparib in Women Who Have Triple-Negative Breast Cancer | Recruiting | USA | 0 |
NCT04690855 | Phase II | Atezolizumab + Talazoparib | A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer (TARA) (TARA) | Recruiting | USA | 0 |
NCT04691375 | Phase I | Pembrolizumab + PY314 PY314 | A Study of PY314 in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04699630 | Phase II | Patritumab deruxtecan | A Study of U3-1402 in Subjects With Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT04711824 | Phase Ib/II | Nab-paclitaxel Cisplatin Durvalumab + Olaparib Paclitaxel Capecitabine Gemcitabine Carboplatin Eribulin | Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases | Recruiting | USA | 0 |
NCT04725331 | Phase Ib/II | BT-001 BT-001 + Pembrolizumab | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | Recruiting | FRA | BEL | 0 |
NCT04726332 | Phase I | Abiraterone + Prednisone + XL102 Fulvestrant + XL102 XL102 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) | Recruiting | USA | 0 |
NCT04762901 | Phase I | Cyclophosphamide + Doxorubicin + Niraparib + Pegfilgrastim Cyclophosphamide + Doxorubicin + Niraparib Niraparib + Paclitaxel Carboplatin + Niraparib + Paclitaxel | LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer | Withdrawn | 0 | |
NCT04770272 | Phase II | Atezolizumab + Carboplatin + Paclitaxel Atezolizumab + Cyclophosphamide + Epirubicin Atezolizumab | Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (neoMono) | Recruiting | DEU | 0 |
NCT04789668 | Phase Ib/II | M7824 + Pimasertib | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | Recruiting | USA | 0 |
NCT04799249 | Phase III | Carboplatin + Gemcitabine Carboplatin + Gemcitabine + Trilaciclib | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) (PRESERVE 2) | Recruiting | USA | FRA | ESP | 9 |
NCT04808362 | Phase Ib/II | OMO-103 | Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours (MYCure) | Recruiting | ESP | 0 |
NCT04837209 | Phase II | Dostarlimab-gxly + Niraparib | Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer (NADiR) | Recruiting | USA | 0 |
NCT04837677 | Phase I | PRT1419 | A Study of PRT1419 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04849364 | Phase II | Capecitabine + GDC-0077 Atezolizumab + Capecitabine Capecitabine + Talazoparib Capecitabine Atezolizumab + Capecitabine + Talazoparib | Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE) | Recruiting | USA | 0 |
NCT04879849 | Phase I | Pembrolizumab + TAK-676 | A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers | Recruiting | USA | 0 |
NCT04915755 | Phase III | Niraparib | Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Either Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease (ZEST) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 18 |
NCT04916002 | Phase II | Cemiplimab + Vidutolimod | CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer | Recruiting | USA | 0 |
NCT04925284 | Phase I | XB002 Nivolumab + XB002 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | Recruiting | USA | 0 |
NCT04927884 | Phase Ib/II | ALT-803 + Cyclophosphamide + PD-L1.t-haNK cells + Sacituzumab govitecan-hziy | A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies | Active, not recruiting | USA | 0 |
NCT04958785 | Phase II | Hu5F9-G4 + Nab-paclitaxel Hu5F9-G4 + Sacituzumab govitecan-hziy Nab-paclitaxel Paclitaxel Hu5F9-G4 + Paclitaxel | Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Nab-Paclitaxel or Paclitaxel Versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Adults With Metastatic Triple-Negative Breast Cancer | Recruiting | USA | 2 |
NCT04986852 | Phase II | Pembrolizumab + Tanibirumab | Olinvacimab With Pembrolizumab in Patients With mTNBC | Recruiting | 1 | |
NCT04992013 | Phase II | Niraparib | Niraparib in Tumors Metastatic to the CNS | Recruiting | USA | 0 |
NCT05001282 | Phase Ib/II | ELU001 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRalpha) | Recruiting | USA | 0 |
NCT05001347 | Phase II | Uliledlimab | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ) in Patients With Ovarian Cancer and Selected Solid Tumors | Recruiting | USA | 0 |
NCT05006794 | Phase I | GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies | Recruiting | USA | 0 |
NCT05007106 | Phase II | MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | 9 |
NCT05020860 | Phase II | Cyclophosphamide + Doxorubicin + Paclitaxel Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab | A Phase II Trial to Correlate Early Clinical Response to Pathologic Outcome in Patients With Early Stage Breast Cancer (RESPONSE) | Not yet recruiting | USA | 0 |
NCT05029999 | Phase I | CDX-1140 + CDX-301 + Pegylated liposomal-doxorubicin | CD40 Agonist, Flt3 Ligand, and Chemotherapy in Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT05043714 | Phase I | NG-641 + Nivolumab | Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (NEBULA) | Recruiting | USA | 1 |
NCT05057013 | Phase Ib/II | HMBD-001 | HMBD-001 in Advanced HER3 Positive Solid Tumours | Recruiting | 1 | |
NCT05064280 | Phase II | Lenvatinib Pembrolizumab | Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases | Recruiting | USA | 0 |
NCT05069935 | Phase I | Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05070247 | Phase I | TAK-500 Pembrolizumab + TAK-500 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05082259 | Phase I | ASTX-660 + Pembrolizumab | ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab (ASTEROID) | Recruiting | 1 | |
NCT05082610 | Phase I | HMBD-002 HMBD-002 + Pembrolizumab | A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab | Recruiting | USA | 0 |
NCT05093387 | Phase I | Carboplatin + Pembrolizumab + SGT-53 | SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer | Not yet recruiting | USA | 0 |
NCT05094804 | Phase Ib/II | Nivolumab + OR2805 OR2805 + Pembrolizumab OR2805 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With a PD-1 Inhibitor | Recruiting | USA | 0 |
NCT05095207 | Phase Ib/II | Abemaciclib + Bicalutamide | Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT05107674 | Phase I | NX-1607 | A Study of NX-1607 in Adults With Advanced Malignancies | Recruiting | 1 | |
NCT05111561 | Phase I | Binimetinib + ZEN-3694 | Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT05112536 | Phase II | Cyclophosphamide + Doxorubicin + Pembrolizumab + Trilaciclib Carboplatin + Paclitaxel + Trilaciclib Trilaciclib | Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT05113966 | Phase II | Sacituzumab govitecan-hziy + Trilaciclib | Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT05123482 | Phase Ib/II | AZD8205 | First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies | Recruiting | USA | 4 |
NCT05143229 | Phase I | Alpelisib + Sacituzumab govitecan-hziy | Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer (ASSET) | Recruiting | USA | 0 |
NCT05144698 | Phase II | RAPA-201 | RAPA-201 Therapy of Solid Tumors | Recruiting | USA | 0 |
NCT05177796 | Phase II | Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel + Panitumumab + Pembrolizumab | Anti-EGFR and Immunotherapy for TN-IBC (TN-IBC) | Recruiting | USA | 0 |
NCT05180006 | Phase II | Atezolizumab Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Ipatasertib Atezolizumab + Bevacizumab | Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (BIS-Program) | Recruiting | FRA | 0 |
NCT05181462 | Phase Ib/II | Carboplatin + Gemcitabine Carboplatin + Gemcitabine + Nidanilimab | Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. (TRIFOUR) | Recruiting | ESP | 0 |
NCT05198843 | Phase Ib/II | Dasatinib + Icosapent Ethyl | Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body | Recruiting | USA | 0 |
NCT05203445 | Phase II | Olaparib + Pembrolizumab | A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer | Recruiting | USA | 0 |
NCT05215106 | Phase II | Durvalumab | Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva) (POP-DURVA) | Recruiting | FRA | 0 |
NCT05233696 | Phase II | Nab-paclitaxel + Pembrolizumab Paclitaxel + Pembrolizumab | Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC | Recruiting | USA | 0 |
NCT05252390 | Phase Ib/II | NUV-868 NUV-868 + Olaparib Enzalutamide + NUV-868 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05255666 | Phase II | MM-398 + Pembrolizumab | Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM) | Recruiting | USA | 0 |
NCT05269381 | Phase I | Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study | Recruiting | USA | 0 |
NCT05272709 | Phase Ib/II | TT-702 | TT-702 in Patients With Advanced Solid Tumours. (CURATE) | Recruiting | 1 | |
NCT05279300 | Phase I | CS5001 | A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas | Recruiting | USA | 1 |
NCT05298592 | Phase I | BMS-986406 + Nivolumab BMS-986406 | A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors | Recruiting | USA | ESP | 0 |
NCT05306444 | Phase I | HBM7008 | HBM7008 -Study on Subjects With Advanced Solid Tumors | Recruiting | 1 | |
NCT05318469 | Phase II | Ivermectin + Pembrolizumab | Ivermectin and Pembrolizumab for the Treatment of Metastatic Triple Negative Breast Cancer | Not yet recruiting | USA | 0 |
NCT05329532 | Phase Ib/II | Modi-1 Modi-1 + Pembrolizumab | Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer (ModiFY) | Recruiting | 1 | |
NCT05332561 | Phase II | Olaparib Ipatasertib Sacituzumab govitecan-hziy GDC-0077 Pertuzumab/trastuzumab/hyaluronidase-zzxf Atezolizumab | Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) | Not yet recruiting | DEU | 0 |
NCT05340413 | Phase II | Olaparib | Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. (RADIOLA) | Recruiting | ESP | 0 |
NCT05358379 | Phase Ib/II | CYC140 | A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | Recruiting | USA | 0 |
NCT05368506 | Phase I | ZN-c3 | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer | Not yet recruiting | USA | 0 |
NCT05374512 | Phase III | Eribulin Nab-paclitaxel Paclitaxel Datopotamab Deruxtecan Carboplatin Capecitabine | A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 16 |
NCT05382286 | Phase III | Pembrolizumab + Sacituzumab govitecan-hziy Carboplatin + Gemcitabine + Pembrolizumab Paclitaxel + Pembrolizumab Nab-paclitaxel + Pembrolizumab | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04) | Recruiting | USA | 0 |
NCT05382299 | Phase III | Nab-paclitaxel Carboplatin + Gemcitabine Sacituzumab govitecan-hziy Paclitaxel | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer (ASCENT-03) | Recruiting | USA | 0 |
NCT05383170 | Phase Ib/II | Cypep-1 + Pembrolizumab | A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers (Catalyst) | Not yet recruiting | USA | ITA | FRA | ESP | 1 |
NCT05383196 | Phase Ib/II | Onvansertib + Paclitaxel | Phase 1b/2 Study of Onvansertib + Paclitaxel in Triple-Negative Breast Cancer (TNBC) | Not yet recruiting | USA | 0 |
NCT05403554 | Phase I | NI-1801 | A Study of NI-1801 in Patients With Mesothelin Expressing Solid Cancers | Recruiting | ITA | FRA | 0 |
NCT05451784 | Phase Ib/II | NUMARZU-001 | Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS (TILS001) | Not yet recruiting | ESP | 0 |
NCT05453825 | Phase II | Irinotecan + Navicixizumab Navicixizumab Navicixizumab + Paclitaxel | A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors | Recruiting | USA | 0 |